MCK McKesson Corporation

McKesson (NYSE:MCK) shares are holding flat within the NYSE Composite Index, performing consistently. The article provides a detailed look into McKesson Corporation's healthcare distribution activities, operational segments, and market positioning, emphasizing its supply chain infrastructure and technology-enabled services. It highlights the company's role in the healthcare sector and its inclusion in broad market indexes.

Generate Investment Management Ltd significantly increased its stake in McKesson Corporation (NYSE:MCK) by 138.4% during the third quarter, now owning 20,267 shares valued at $15.66 million. Other institutional investors like Solstein Capital LLC and Abound Wealth Management also boosted their holdings. The report also details analyst ratings, insider transactions, and McKesson's recent financial performance and dividend announcement.

Deutsche Bank analyst George Hill raised the price target on McKesson Corporation (NYSE:MCK) to $904 from $861, reiterating a Buy rating, despite the planned spin-off of its med-surgical business by the end of 2027. The company's fiscal 2026 profit forecast was raised earlier in November due to strong oncology and specialty drug distribution. Although revenue slightly missed expectations in the most recent quarter, the company's adjusted EPS significantly beat estimates.

Deutsche Bank analyst George Hill raised the price target for McKesson Corporation (MCK) to $904 from $861, maintaining a Buy rating despite the company's plan to spin off its med-surgical business by the end of 2027. This positive outlook is supported by McKesson's raised fiscal 2026 profit forecast, driven by strong growth in oncology and specialty drug distribution, which offer higher margins. The company's recent financial results also exceeded profit estimates, although revenue was slightly below expectations.

This article analyzes McKesson (MCK) stock, referencing its average brokerage recommendation (ABR) of 1.47, indicating a Strong Buy to Buy consensus among 17 brokerage firms. However, it cautions against solely relying on ABRs due to potential bias, recommending the Zacks Rank as a more reliable tool for predicting stock price movements, which currently rates MCK as a Zacks Rank #3 (Hold).

Carnegie Investment Counsel significantly increased its stake in McKesson Corporation, now holding 2,765 shares valued at $2.14 million. This comes as McKesson outperformed EPS expectations and analysts raised price targets, reflecting a "Moderate Buy" consensus. The company also announced a quarterly dividend of $0.82.